5-Azacitidine prolongs overall survival in patients with myelodysplastic syndrome - A systematic review and meta-analysis

Keyphrases

• 5-azacytidine 100%
• Adverse Events 20%
• Best Supportive Care 20%
• Chemotherapy 20%
• Confidence Interval 60%
• Conventional Care 20%
• Decitabine 60%
• Dichotomous Data 20%
• Drug Type 20%
• Event Data 20%
• Hazard Ratio 60%
• High-risk Myelodysplastic Syndrome 20%
• Hypomethylating Agents 60%
• Meta-analysis 100%
• Mortality Hazard 20%
• Myelodysplastic Syndrome 100%
• Overall Response Rate 20%
• Overall Survival 100%
• Overall Survival Time 20%
• Overall Time 20%
• Randomized Controlled Trial 20%
• Relative Risk 20%
• Response Rate 20%
• Subgroup Analysis 20%
• Systematic Meta-analysis 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 20%
• Azacitidine 100%
• Chemotherapy 20%
• Decitabine 60%
• Myelodysplastic Syndrome 100%
• Overall Survival 100%
• Randomized Controlled Trial 20%
• Survival Time 20%

Biochemistry, Genetics and Molecular Biology

• Azacitidine 100%
• Decitabine 60%
• Overall Survival 100%
• Randomized Controlled Trial 20%
• Survival Time 20%